Following the discovery of epidermal growth factor receptor (EGFR) mutations in non‐small cell lung cancer (NSCLC), first‐generation EGFR‐tyrosine kinase inhibitor (EGFR‐TKI) (gefitinib or erlotinib) therapy has been shown to yield better progression‐free survival (PFS) (median: 10.8–5.7 vs. 5.8–5.2 months) than standard cytotoxic chemotherapy and comparable overall survival (OS) (medians: 30.5–21.6 vs. 23.6–21.9 months) in chemo‐naïve patients with EGFR‐mutant tumors.1, 2. The gene discussed is EGFR; the disease is lung cancer.